United States Patent 11,596,614: Seladelpar 5 mg and 10 mg Patent Scope, Exclusivity, and Generic Risk

U.S. Patent No. 11,596,614 protects methods of treating an intrahepatic cholestatic disease with a daily 5 mg or 10 mg dose of seladelpar, calculated as seladelpar active moiety. The patent also covers oral, once-daily administration and the seladelpar L-lysine dihydrate salt. Its claims are method-of-use claims, not composition-of-matter, formulation, or manufacturing claims.

The commercial relevance is highest for Livdelzi, the seladelpar product approved by the FDA for primary biliary cholangitis, or PBC. The approved regimen is 10 mg orally once daily. That regimen maps directly onto independent claim 9 and dependent claims 10 through 16.[1]

What does U.S. Patent 11,596,614 protect?

The patent has two independent claims:

Claim	Protected dose	Disease scope	Drug form	Administration
1	5 mg daily	Intrahepatic cholestatic disease	Seladelpar or salt	Not specified
9	10 mg daily	Intrahepatic cholestatic disease	Seladelpar or salt	Not specified

The dependent claims narrow those methods as follows:

Claims	Limitation
2, 10	Seladelpar L-lysine dihydrate salt
3, 11	Oral administration
4, 12	Seladelpar L-lysine dihydrate salt administered orally
5, 13	Once-daily administration
6, 14	L-lysine dihydrate salt administered once daily
7, 15	Seladelpar or salt administered orally once daily
8, 16	L-lysine dihydrate salt administered orally once daily

The patent therefore creates two principal protected dosing positions:

5 mg seladelpar per day.
10 mg seladelpar per day.

The 10 mg claims are the commercially important group because they correspond to the FDA-approved Livdelzi dosage.[1]

How broad is the “intrahepatic cholestatic disease” limitation?

The disease limitation is materially broader than PBC. The claims do not expressly restrict treatment to primary biliary cholangitis. “Intrahepatic cholestatic disease” can encompass a group of disorders in which bile formation or bile transport is impaired within the liver.

Potentially relevant disease categories include:

Primary biliary cholangitis.
Primary sclerosing cholangitis.
Progressive familial intrahepatic cholestasis.
Other inherited or acquired intrahepatic cholestatic disorders.

Claim scope would depend on the patent specification, prosecution history, claim construction, and the medical meaning of the disease term at the relevant time. A generic or competing product directed only to PBC would still fall within the literal disease language if the administered treatment satisfies the other claim elements.

The claims do not require:

A particular stage of liver disease.
A particular biomarker level.
A specified alkaline phosphatase response.
Concomitant ursodeoxycholic acid.
Failure or intolerance of another therapy.
A particular patient age.
A particular duration of treatment.
A particular formulation or release profile.

That breadth increases the potential method-of-use coverage beyond the current FDA label.

What is the difference between the 5 mg and 10 mg claims?

Claim 1 covers a daily dose of 5 mg calculated as seladelpar. Claim 9 covers a daily dose of 10 mg calculated on the same basis.

The “calculated as seladelpar” language matters because the commercial product is a salt. The mass of seladelpar L-lysine dihydrate administered as a pharmaceutical product is not necessarily identical to the mass of seladelpar active moiety. The claims measure the dose against the seladelpar component rather than the total salt weight.

This drafting approach reduces ambiguity over whether a dose qualifies when administered as the lysine dihydrate salt. A product label expressing the dose as 10 mg seladelpar active moiety would align closely with claim 9 and the dependent 10 mg claims.

The claims do not expressly require once-daily administration in their independent form. Claims 5 through 8 and 13 through 16 add that limitation. A 10 mg daily dose administered in divided doses could potentially implicate claim 9 even if it does not satisfy the once-daily dependent claims, subject to claim construction and proof of actual administration.

What formulations are protected by Patent 11,596,614?

Patent 11,596,614 does not claim a formulation as such. It does not recite:

Tablet composition.
Capsule composition.
Excipients.
Particle size.
Dissolution profile.
Bioavailability.
Immediate-release or extended-release characteristics.
Manufacturing parameters.
Stability specifications.

A formulation may infringe indirectly when it is supplied for use in a claimed treatment regimen. Direct method infringement, however, generally turns on performance of the claimed method rather than ownership of the formulation alone.

The express reference to seladelpar L-lysine dihydrate in claims 2, 4, 6, 8, 10, 12, 14 and 16 is a salt-form limitation within a treatment method. It is not a standalone claim to the salt or to a pharmaceutical composition containing the salt.

What is the FDA status of seladelpar?

The FDA approved Livdelzi, containing seladelpar, on June 14, 2024, for adults with primary biliary cholangitis without cirrhosis or with compensated cirrhosis who have an inadequate response to ursodeoxycholic acid or cannot tolerate it.[1]

The approved dosage is 10 mg orally once daily, with or without food. The label does not authorize use in patients with decompensated cirrhosis.[1]

The approval was granted under the accelerated approval pathway based principally on biochemical evidence, including reduction in alkaline phosphatase. Continued approval is subject to verification of clinical benefit in a confirmatory study.[1]

FDA milestone	Date
Livdelzi approval	June 14, 2024
Approved active ingredient	Seladelpar
Approved disease	Primary biliary cholangitis
Approved dose	10 mg orally once daily
Approval pathway	Accelerated approval
Sponsor at approval	CymaBay Therapeutics
Current commercial owner	Gilead Sciences following acquisition of CymaBay

Gilead completed its acquisition of CymaBay in 2024, obtaining seladelpar and the Livdelzi commercial program.[2]

What is the Orange Book status of U.S. Patent 11,596,614?

The relevant question is whether Patent 11,596,614 is listed in the FDA Orange Book for the Livdelzi NDA and, if listed, whether it is identified with a method-of-use patent code.

A listed patent can affect the timing of ANDA approval. A generic applicant generally must certify against each listed patent under the Hatch-Waxman framework. A Paragraph IV certification alleges that the patent is invalid, unenforceable, or will not be infringed.[3]

For Livdelzi, the commercial exposure is concentrated in the 10 mg regimen because the approved product label expressly directs 10 mg once daily. If Patent 11,596,614 is listed against that use, the patent would present a direct Orange Book barrier to an ANDA seeking the same labeled indication and dose.

The patent does not appear, based on the claim set supplied, to provide a composition-of-matter barrier to all seladelpar products. Its principal regulatory value is use-code protection around the dosing regimen and disease category.

When does Patent 11,596,614 lose exclusivity?

The patent issued on March 7, 2023. Its nominal statutory term is expected to extend into 2039, based on the underlying U.S. patent-family filing chronology. The precise expiration date depends on the patent’s calculated term adjustment and any applicable term extension recorded by the USPTO.

The patent should be analyzed separately from FDA regulatory exclusivity:

Exclusivity layer	Relevance
Patent 11,596,614	Protects 5 mg and 10 mg seladelpar treatment methods
FDA orphan-drug exclusivity	Not the apparent basis of Livdelzi’s PBC approval
New-chemical-entity exclusivity	Potentially relevant to the active ingredient and approval timing
Accelerated-approval status	Does not itself create a permanent market barrier
Other patents	May cover the molecule, salt, formulation, or additional uses

FDA regulatory exclusivity and patent expiration are separate. A generic applicant may face an Orange Book patent dispute even after a period of FDA exclusivity has ended. Conversely, a patent may remain in force after regulatory exclusivity expires.

How strong is the patent estate for seladelpar?

Patent 11,596,614 is strongest against a product that:

Contains seladelpar or the L-lysine dihydrate salt.
Is marketed for an intrahepatic cholestatic disease.
Uses a 5 mg or 10 mg daily seladelpar dose.
Directs oral, once-daily use.
Seeks an FDA label overlapping the claimed disease and regimen.

Its limitations are equally important. The patent does not, on its face from the supplied claims, monopolize:

Seladelpar as a chemical compound.
Every dose outside 5 mg and 10 mg.
Every route of administration.
Every pharmaceutical formulation.
Every use of seladelpar unrelated to intrahepatic cholestatic disease.
Manufacture of seladelpar or its salt.

The patent is therefore a targeted regimen patent. It is commercially significant because the protected 10 mg regimen is the FDA-approved Livdelzi dose, but it is narrower than a composition-of-matter patent.

Which companies are challenging seladelpar patent rights?

No Paragraph IV challenger, ANDA applicant, or patent litigation defendant is identified in the claim information supplied. Public challenge risk should be assessed through FDA Orange Book updates, FDA Paragraph IV notices, USPTO assignment and prosecution records, and federal court filings.

The most likely challenger profile would be a generic manufacturer filing an ANDA for seladelpar after any applicable regulatory exclusivity period. A challenge would likely focus on:

Written-description or enablement issues.
Obviousness of the 5 mg and 10 mg dosing regimens.
Anticipation by clinical or patent disclosures.
Claim construction of “intrahepatic cholestatic disease.”
Whether a proposed label induces infringement.
Whether the relevant patent is properly listed for the approved use.

A generic applicant could also seek a skinny label that omits a patented indication or dosing instruction. That strategy is less effective if the proposed label still directs the same 10 mg regimen for PBC.

What generic launch scenarios exist?

Full-label ANDA launch

A full-label ANDA would seek approval for PBC using the FDA-approved 10 mg once-daily regimen. That product would present the clearest infringement risk under claims 9, 10, 12, 14 and 16 if the patent remains listed and enforceable.

Skinny-label launch

A skinny label could omit a patented use or dosing instruction. Its viability would depend on the remaining label language, promotional conduct, prescribing context and whether the approved indication can be practiced without the patented regimen.

Alternative-dose launch

A product labeled only for a dose other than 5 mg or 10 mg would reduce literal overlap with the supplied claims. It would not eliminate risk from other seladelpar patents or from induced infringement theories based on actual use.

Non-oral or divided-dose launch

A label excluding oral or once-daily administration could avoid certain dependent claims. It would not necessarily avoid claims 1 or 9, which do not expressly require oral or once-daily administration.

Does seladelpar face biosimilar risk?

No. Seladelpar is a small-molecule drug, not a biologic. The relevant follow-on pathway is an ANDA under the Hatch-Waxman Act, not a biosimilar application under the Public Health Service Act.[3]

The commercial risks are therefore generic substitution, Paragraph IV litigation, skinny-label entry and potential authorized-generic strategies. Biosimilar interchangeability and biologic reference-product exclusivity are not relevant to Livdelzi.

How does Patent 11,596,614 compare with competing PBC products?

Product	Active ingredient	FDA status	Main commercial distinction
Livdelzi	Seladelpar	Approved June 2024	10 mg oral once daily; PBC
Iqirvo	Elafibranor	Approved June 2024	Alternative PPAR-directed PBC therapy
Ocaliva	Obeticholic acid	Regulatory status has changed over time	Earlier PBC competitor with significant safety and benefit-risk history
Ursodeoxycholic acid	Ursodiol	Established therapy	Background standard treatment rather than a direct patent-comparable entrant

Seladelpar competes in a concentrated PBC market. The patent’s commercial value depends on maintaining the 10 mg regimen as the central labeled and prescribed dose. A successful competing therapy would not infringe Patent 11,596,614 merely by treating PBC if it does not use seladelpar.

What litigation and settlement issues matter?

A Paragraph IV suit involving a listed patent would generally trigger the statutory 30-month stay framework if the patent owner or NDA holder sues within the applicable period.[3] A settlement could establish a deferred generic launch date, an authorized-generic arrangement, a license, or restrictions on the challenged use.

No settlement agreement or patent litigation outcome is established by the supplied claim text. The key diligence items are:

Orange Book patent listing and use code.
ANDA Paragraph IV notices.
Complaints filed under 35 U.S.C. §271(e)(2).
Patent-term-adjustment calculation.
Continuation and divisional applications.
Any license or settlement involving Gilead, CymaBay or a generic applicant.
Post-approval changes to the Livdelzi label.

Key Takeaways

Patent 11,596,614 is a method-of-treatment patent for seladelpar in intrahepatic cholestatic disease.
Independent claims cover daily 5 mg and 10 mg seladelpar doses.
The claims calculate dose as seladelpar active moiety, which is important for the L-lysine dihydrate salt.
Claims 2 through 8 and 10 through 16 add the salt, oral route and once-daily regimen.
The FDA-approved Livdelzi regimen, 10 mg orally once daily for PBC, directly overlaps the most commercially important claims.
The patent does not claim seladelpar composition of matter, a formulation, manufacturing process or every seladelpar use.
The patent’s nominal term extends into 2039, subject to the recorded patent-term calculation.
Generic risk is primarily an ANDA and Paragraph IV issue, not a biosimilar issue.
The strength of the patent is highest against a full-label generic using 10 mg once-daily seladelpar for PBC.
Other seladelpar patents may independently affect molecule, salt, formulation and manufacturing freedom to operate.

FAQs

Is Patent 11,596,614 a composition-of-matter patent for seladelpar?

No. The supplied claims are treatment-method claims. They require administering seladelpar or a salt to treat an intrahepatic cholestatic disease.

Does a 10 mg Livdelzi dose infringe every claim in the patent?

No. It most directly corresponds to claim 9 and the dependent 10 mg claims. It does not satisfy the 5 mg limitation in claim 1.

Does the patent cover primary biliary cholangitis?

Yes, PBC is the principal commercial disease relevant to the patent and is an intrahepatic cholestatic disease within the apparent claim scope.

Can a generic sell seladelpar for a non-cholestatic indication?

Potentially, subject to other patents and regulatory requirements. The supplied claims require treatment of an intrahepatic cholestatic disease.

Does changing from once-daily dosing avoid the patent?

It may avoid the once-daily dependent claims, but claims 1 and 9 do not expressly require once-daily administration. The analysis would depend on the exact label, actual use and claim construction.

What is the primary commercial risk after patent expiry?

The main risk is generic entry into the 10 mg once-daily PBC market. Before expiry, risk centers on Paragraph IV litigation, skinny-label strategies, settlements and possible licensing arrangements.

References

U.S. Food and Drug Administration. (2024, June 14). FDA grants accelerated approval to seladelpar for primary biliary cholangitis. https://www.fda.gov
Gilead Sciences, Inc. (2024). Gilead completes acquisition of CymaBay Therapeutics. https://www.gilead.com
U.S. Code. 21 U.S.C. §355; 35 U.S.C. §271(e)(2). Hatch-Waxman Act provisions governing abbreviated new drug applications and patent litigation.
United States Patent and Trademark Office. (2023). U.S. Patent No. 11,596,614. Patent Center. https://patentcenter.uspto.gov
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugsatfda

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Gilead Sciences Inc	LIVDELZI	seladelpar lysine	CAPSULE;ORAL	217899-001	Aug 14, 2024		RX	Yes	Yes	11,596,614	⤷ Start Trial				TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3119384	⤷ Start Trial	C20253004	Finland	⤷ Start Trial
European Patent Office	3119384	⤷ Start Trial	CA 2025 00025	Denmark	⤷ Start Trial
European Patent Office	3119384	⤷ Start Trial	PA2025529	Lithuania	⤷ Start Trial
European Patent Office	3119384	⤷ Start Trial	301338	Netherlands	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 11,596,614

Which drugs does patent 11,596,614 protect, and when does it expire?

Summary for Patent: 11,596,614